4.5 Article

Prevalence and Risk Factors for Pancreatic Insufficiency After Partial Pancreatectomy

期刊

JOURNAL OF GASTROINTESTINAL SURGERY
卷 26, 期 7, 页码 1425-1435

出版社

SPRINGER
DOI: 10.1007/s11605-022-05302-3

关键词

Post-pancreatectomy diabetes mellitus; Post-pancreatectomy exocrine enzyme insufficiency; Post-pancreatectomy pancreatic insufficiency; Partial pancreatectomy

资金

  1. Columbia University Pancreas Center
  2. Columbia University Medical Center Department of Obstetrics Gynecology
  3. Columbia University Medical Center Department of Surgery

向作者/读者索取更多资源

This study determines the prevalence, timing, and predictors of diabetes and exocrine pancreatic insufficiency after pancreatectomy, providing important information for preoperative counseling and risk management strategies.
Background This study aimed to determine the rate, timing, and predictors of diabetes and exocrine pancreatic insufficiency after pancreatectomy in order to inform preoperative patient counseling and risk management strategies. Methods Using prescription claims as a surrogate for disease prevalence, IBM Watson Health MarketScan was queried for claims patterns pre- and post-pancreatectomy. Multivariable models explored associations between clinical characteristics and medication use within 2 years of surgery. Results In total, 18.96% of 2,848 pancreaticoduodenectomy (PD) patients and 18.95% of 1,858 distal pancreatectomy (DP) patients had preoperative diabetic medication prescription claims. Fewer (6.6% and 3.88%, respectively) had pancreatic enzyme replacement therapy (PERT) claims. Diabetic medication claims increased to 28.69% after PD and 38.59% after DP [adjusted relative risk (aRR) = 1.36 (95% CI 1.27, 1.46)]. Other associated factors included age > 45, medical comorbidity, and obesity. The incidence of new diabetic medication claims among medication naive patients was 13.78% for PD and 24.7% for DP (p < 0.001) with a median 4.7 and 4.9 months post-operatively. The prevalence of PERT claims was 55.97% after PD and 17.06% after DP [aRR = 0.32 (0.29, 0.36)]. The incidence of postoperative PERT claims 53.98% (PD) and 14.84% (DP) (p < 0.0001). The median time to new PERT claim was 3.0 (PD) and 3.2 (DP) months, respectively. Claims for both diabetic medications and PERT rose sharply after surgery and plateaued within 6 months. Conclusions This study defines prevalence, timing, and predictors for post-pancreatectomy insufficiency to inform preoperative counseling, risk modification strategies, and interventions related to quality of life.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据